FDA
-
-
-
-
-
-
-
Nektar gets two presentations at dermatology meeting for drug trials
-
-
-
-
-
-
-
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
-
-
-
-
-
-
-
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
-
-
-
-
-
-
-
Nektar Therapeutics Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Receives Fast Track Designation for Rezpegaldesleukin
-
-
-
-
-
-
-
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
-
-
-
-
-
-
-
Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

